February 19th 2025
Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.
February 19th 2025
February 18th 2025
February 17th 2025
February 14th 2025
January 5th 2025
January 1st 2025
December 31st 2024
December 29th 2024
February 1st 2025
January 12th 2025
January 7th 2025
November 30th 2024